Manufacturer
Sun Pharmaceutical Industries Ltd.(INDIA)
Registraction Number
MAL24076018AZ
Contents:
Each capsule contains 150 mg of nintedanib (free base), which corresponds to 180.6 mg of nintedanib esilate. The capsule shell includes ingredients like gelatine, glycerol, titanium dioxide, iron oxide red and yellow, and black ink.
Indication:
NINTESUN 150 is primarily used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) where lung fibrosis continues to worsen. It is also indicated for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Instructions: